A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1

被引:0
作者
Rieko Nakamura
Yoshiro Saikawa
Koushi Kumagai
Tsuyoshi Kiyota
Masaki Ohashi
Masashi Yoshida
Tetsuro Kubota
Koichiro Kumai
Masaki Kitajima
机构
[1] Keio University,Department of Surgery, School of Medicine
[2] Keio University Hospital,Center for Comprehensive and Advanced Medicine
[3] Keio University,Center for Diagnostic and Therapeutic Endoscopy
来源
International Journal of Clinical Oncology | 2007年 / 12卷
关键词
Gastric cancer; Liver metastases; Combination chemotherapy; S-1;
D O I
暂无
中图分类号
学科分类号
摘要
We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1–5, 8–12, and 15–19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+α lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.
引用
收藏
页码:295 / 299
页数:4
相关论文
共 79 条
[1]  
Vanhoefer U(2000)Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative group J Clin Oncol 18 2648-2657
[2]  
Rougier P(2003)Randomized phase III trial of fluorouracil alone versus fluororouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54-59
[3]  
Wike H(1999)An early phase II study of oral S-1, a newly developed 5-fluoropyrimidine derivative for advanced and recurrent gastrointestinal cancers Oncology 67 202-210
[4]  
Ohtsu A(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-1720
[5]  
Shimada Y(2000)Phase II study for S-1, a novel derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191-197
[6]  
Shirao K(2003)Phase I/II study of S-1 with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207-2212
[7]  
Sugimachi K(1993)Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors Surgery 114 799-805
[8]  
Maehara Y(2001)Benefits and limits of resection for gastric metastases Am J Surg 181 279-283
[9]  
Horikoshi N(2002)Hepatic resection for metastatic tumors from gastric cancer Ann Surg 1 86-91
[10]  
Sakata Y(2000)Transcatheter therapy of gastric cancer metastastic to the liver: preliminary results J Gastroenterol 35 907-911